Definium Therapeutics to present Phase 3 Emerge topline data for DT120 ODT in major depressive disorder June 22

Definium Therapeutics, Inc.

DFTX

0.00

Definium Therapeutics scheduled a June 22, 2026 webcast to present topline Phase 3 Emerge results for DT120 ODT in major depressive disorder.
The trial tested a single-dose treatment against placebo, with efficacy assessed over several weeks.
Management plans to discuss whether DT120 produced meaningful symptom improvement versus placebo, alongside the overall safety profile, without releasing detailed metrics in advance.
Emerge is the first of two pivotal Phase 3 studies; a second trial, Ascend, is running with an additional lower-dose arm to support the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260621839059) on June 21, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.